Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors
This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-283 in patients with solid tumours.
Solid Tumors
DRUG: BGB-283
Number of participants with adverse events in phase 1a, From first dose to within 28 days of last dose of BGB-283, within 1 years in average|Objective response rate based on RECIST Version 1.1 in subjects with selected tumor types in phase 1b, From the first administration of the investigational product to the end of the study treatment, within 1 year in average
Area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration (AUClast) in phase 1a, During first 2 weeks|Area under the plasma concentration-time curve from time 0 to infinity time in (AUCâˆž) in phase 1a, During first 2 weeks|Maximum plasma concentration (Cmax) in phase 1a, During first 2 weeks|Time to reach maximum plasma concentration (tmax) in phase 1a, During first 2 weeks|Terminal elimination half-life (t1/2) in phase 1a, During first 2 weeks|Tumor response in phase 1a, Every 6 weeks from first dose until the date of first documented progression or date of death from any cause, whichever came first, within 1 year in average|Number of participants with adverse events in phase 1b, From first dose to within 28 days of last dose of BGB-283, within 1 year in average|Progression-free survival (PFS), The interval from study treatment initiation until the determination of disease progression or death, within 1 year in average
This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-283 in patients with solid tumours.